Explore 3 Stock Ideas & Industry Insights Download Free Report

Elixxer Ltd

Healthcare CA ELXR

0.035CAD
0.00(0%)

Last update at 2026-06-02T13:30:00Z

Day Range

0.040.04
LowHigh

52 Week Range

1.151.15
LowHigh

Fundamentals

  • Previous Close 0.04
  • Market Cap13.05M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-2.50401M
  • Revenue TTM0.00002M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.04M
  • Diluted EPS TTM-1.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -3.46685M -4.00831M -14.09019M -3.66271M -9.78346M
Minority interest - - - - -
Net income -3.46685M -4.00831M -14.17232M -3.66271M -9.78346M
Selling general administrative 0.49M 1.28M 2.22M 2.07M 3.29M
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation - - 0.00000M 0.00196M 0.00197M
Ebit - - - -2.09722M -5.44451M
Ebitda - - -11.63913M -1.93687M -7.71789M
Depreciation and amortization - - - - -
Non operating income net other - - - - -
Operating income -0.48969M -1.28345M -2.42384M -2.09722M -5.44451M
Other operating expenses - - - - -
Interest expense 2.22M 2.61M 2.45M 1.72M 2.06M
Tax provision - - - - -
Interest income - 0.00000M 0.08M 0.04M 1.09M
Net interest income -2.21846M -2.60717M -3.06393M -1.68147M -1.61007M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - - - -
Total revenue 0.00000M 0.00000M 0.08M 0.00000M 0.02M
Total operating expenses 0.49M 1.28M 2.51M 2.10M 5.46M
Cost of revenue - - - - -
Total other income expense net -0.75870M -0.11769M -8.60242M 0.12M -2.72889M
Discontinued operations - - - - -
Net income from continuing ops -3.46685M -4.00831M -14.09019M -3.66271M -9.78346M
Net income applicable to common shares - - -14.17232M -3.66271M -9.78346M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 2.13M 2.81M 5.37M 16.84M 20.81M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - - -
Total liab 15.23M 12.41M 10.95M 8.45M 16.06M
Total stockholder equity -13.09285M -9.60042M -5.58488M 8.38M 4.76M
Deferred long term liab - - - - -
Other current liab - - - - -
Common stock - - - 53.26M 49.57M
Capital stock 53.44M 53.44M 53.44M 53.26M 49.57M
Retained earnings -87.97754M -84.51070M -80.50239M -66.33007M -62.66736M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.32M 0.36M
Cash 0.02M 0.02M 0.07M 0.30M 2.10M
Cash and equivalents - - - - -
Total current liabilities 15.23M 12.41M 7.34M 8.45M 16.06M
Current deferred revenue - - - - -
Net debt 11.89M 9.64M 7.96M 6.24M 10.99M
Short term debt - - - - -
Short long term debt 11.91M 9.66M 4.41M 6.54M 13.09M
Short long term debt total - - - - -
Other stockholder equity - - 4.04M 4.79M 4.33M
Property plant equipment - - - - 0.00555M
Total current assets 0.07M 0.03M 2.53M 13.70M 2.33M
Long term investments 0.82M 0.75M 2.84M 0.69M 15.99M
Net tangible assets - - - 8.38M 4.76M
Short term investments - 0.00000M 2.41M 13.28M -
Net receivables - - - 0.11M 0.22M
Long term debt - - 3.61M - -
Inventory - - - - -
Accounts payable - - 2.93M 1.89M 1.54M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - - -
Deferred long term asset charges - - - - -
Non current assets total 2.06M 2.78M 2.84M 3.14M 18.49M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 0.00000M 2.35M 2.32M 2.19M 1.06M
Change to liabilities - - 1.02M -1.00201M 0.54M
Total cashflows from investing activities - - - 2.19M 1.06M
Net borrowings - 0.00000M 1.04M 0.16M 2.74M
Total cash from financing activities - 0.00000M 0.46M 0.03M 3.13M
Change to operating activities - - - - -
Net income -3.46685M -4.00831M -14.17232M -3.66271M -9.78346M
Change in cash 0.00000M -0.04512M -0.23634M -1.80099M 1.18M
Begin period cash flow 0.02M 0.07M 0.30M 2.10M 0.92M
End period cash flow 0.02M 0.02M 0.07M 0.30M 2.10M
Total cash from operating activities 0.00000M -2.39859M -3.02085M -4.01901M -3.01302M
Issuance of capital stock - - - 0.00000M 0.40M
Depreciation - - 0.00000M 0.00196M 0.00197M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - 0.11M 0.17M -0.12246M
Sale purchase of stock - 0.00000M -0.58159M -0.12929M -
Other cashflows from financing activities - - - - 0.26M
Change to netincome - - - 0.48M 6.35M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.52M -0.08786M 1.13M -0.83567M 0.42M
Stock based compensation - - 0.00000M 0.00079M 0.41M
Other non cash items 2.22M 2.61M 1.11M 0.54M 9.50M
Free cash flow 0.00000M -2.39859M -3.02085M -4.01901M -3.01302M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ELXR
Elixxer Ltd
- -% 0.04 - - 767773.80 2.67 113.53 -2.6271
RX
Biosyent Inc.
0.12 0.87% 13.95 19.10 15.85 3.96 4.11 3.31 11.03
DB
Decibel Cannabis Company Inc
-0.005 4.17% 0.12 - 8.67 0.67 1.20 0.99 17.75
ZYUS
ZYUS Life Sciences Corporation
- -% 0.50 - - 108.48 4.41 140.29 -4.258
LSL
LSL Pharma Group Inc.
- -% 0.33 20.75 - 1.88 1.89 2.85 10.19

Reports Covered

Stock Research & News

Profile

Elixxer Ltd. operates as a cannabis investment firm in Canada, Australia, Italy, Jamaica, and Switzerland. It invests in cultivation, production, and/or sale of medical cannabis and cannabis-derived products in the pharmaceutical sector. The company was formerly known as LGC Capital Ltd. and changed its name to Elixxer Ltd. in August 2019. Elixxer Ltd. was incorporated in 2004 and is based in Montreal, Canada.

Elixxer Ltd

1100 Boulevard Rene- Levesque Ouest, Montreal, QC, Canada, H5B 4N4

Key Executives

Name Title Year Born
Mr. Ferras Zalt Chairman & Interim CEO 1963
Ms. Kym No C.M.A., CPA Corp. Controller & Interim CFO NA
Mr. Guy Charette L.L.B., LL.B. Legal Council 1954
Ms. Jeanne van Wyk VP of Communications NA
Mr. Daniel Lubienietzky VP of Corp. Devel. NA
Mr. Richard Widmann EVP of Commercial 1968
Mr. Michael Kozub Corp. Sec. NA
Ms. Kym No C.M.A., CPA Corporate Controller & Interim CFO NA
Ms. Jeanne van Wyk Vice President of Communications NA
Mr. Daniel Lubienietzky VP of Corporate Development NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.